Kventiax film-coated tablets 100 mg blister No. 30

Kventiax is an antipsychotic drug. Indications for use - treatment of schizophrenia, treatment of bipolar disorder.

Warehouse

Contraindication

Hypersensitivity to the active substance or to any component of the drug.

Method of application

Treatment of schizophrenia and moderate to severe manic episodes in bipolar disorder

Kventiax® should be administered twice daily. The daily dose for the first four days is: 50 mg (day one), 100 mg (day two), 200 mg (day three) and 300 mg (day four). After 4 days of treatment, the dose should be titrated to a usually effective dose of 300–450 mg/day. Depending on clinical response and tolerability, the dose may be adjusted within the range of 150 mg to 750 mg/day.

Treatment of moderate to severe manic episodes in bipolar disorder

Kventiax® should be administered twice daily. The daily dose for the first four days is: 50 mg (day one), 100 mg (day two), 200 mg (day three) and 300 mg (day four). Further dose adjustments to 800 mg/day should be made in increments of no more than 200 mg per day.

Depending on clinical response and tolerability, the dose may be adjusted within the range of 200 mg to 800 mg/day. The effective dose is usually in the range of 400–800 mg/day.

Application features

Since Quetiapine® is indicated for the treatment of schizophrenia, bipolar disorder and the concomitant treatment of depressive episodes in patients with major depressive disorder (MDD), the safety profile of the drug should be carefully considered in light of the individual patient's diagnosis and the dose being taken.

The long-term efficacy and safety of concomitant therapy in patients with TDR have not been evaluated, but the long-term efficacy and safety of monotherapy with the drug in adult patients have been studied.

Pregnant women

Pregnancy

The safety and efficacy of quetiapine in pregnant women have not been established.

Children

The safety and efficacy of quetiapine in children have not been studied, so the drug is not used in children and adolescents.

Drivers

Given that quetiapine primarily acts on the central nervous system, patients are advised not to drive or operate machinery until individual sensitivity to such effects has been determined.

Overdose

Survival has been reported in clinical trials following acute overdoses of up to 30 g of quetiapine. Most patients with overdoses reported no adverse events or recovered completely from such events. A fatal outcome was reported in a clinical trial following an overdose of 13.6 g of quetiapine. During post-marketing use, reports of quetiapine overdose resulting in death, coma, or QT prolongation have been very rare.

Side effects

From the side of the blood and lymphatic system - decreased hemoglobin level, leukopenia, decreased neutrophil count, increased eosinophil count, thrombocytopenia, anemia, agranulocytosis, neutropenia.

On the part of the immune system - hypersensitivity (including allergic skin reactions), anaphylactic reaction.

On the part of the endocrine system - hyperprolactinemia, inadequate secretion of antidiuretic hormone.

Storage conditions

The medicine does not require any special storage conditions.

Keep out of reach of children.